Vancomycin
FDA approved · RxGlycopeptide antibiotic
Also known as: Vancocin, Vancomycin Hydrochloride, Vancomicina, Vancomycine, Vancomycinum, Vancocin HCL, Vancomycin Lilly, Sulfate, Vancomycin
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 702 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Vancomycin is a glycopeptide antibiotic originally derived from the soil bacterium Amycolatopsis orientalis. It works by binding to building blocks of the bacterial cell wall, blocking cell wall construction in Gram-positive bacteria. It is a prescription medicine sold under names including Vancocin and Vancomycin Hydrochloride.
What the evidence shows
Vancomycin is FDA-approved for treating serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus, and in oral form for Clostridioides difficile-associated diarrhea. It is supported by decades of clinical use, nearly 700 registered human trials reaching Phase 4, and a very large published literature.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin
Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures
Copper Use as Protection Against Antimicrobial Resistance in the ICU
Hospital Avoidance Strategies for ABSSSI
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
Duodenal infusion of donor feces for recurrent Clostridium difficile.
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
Sources
- PubChem compound record (CID 14969)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.